Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 9, 2026Journal of Dermatological TreatmentOpen Access

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL

View Full Paper
Ask AI
Bookmark
Share

Authors

RCRaj ChovatiyaMZMatthew ZirwasMGMelinda Gooderham

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates abrocitinib's safety and efficacy in atopic dermatitis patients, indicating its real-world applicability.

Key Points

  • The aim was to assess the safety and efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis.
  • Prospective, multicenter, open-label study.
  • Eligible patients received abrocitinib 100 mg or 200 mg daily, with dose adjustments permitted.
  • Safety and exploratory efficacy endpoints were carefully monitored.
  • 312 patients participated, with 120 (38.5%) on 100 mg and 192 (61.5%) on 200 mg initial doses.
  • TEAEs reported in 78.2% of patients, with dose changes occurring in 12.5% due to TEAEs.
  • Observations showed rapid improvements in atopic dermatitis severity over 72 weeks.

Cite This Study

Chovatiya et al. (2026) studied this question.

synapsesocial.com/papers/6a782d4e2e1896536c8404dahttps://doi.org/10.1080/09546634.2026.2712186
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)2026
  2. 2Real-World Use of Abrocitinib for Moderate-to-Severe Atopic Dermatitis in the United States Based on Electronic Health Records and Administrative Claims2026
  3. 3Treatment Trajectories and Dose Optimization of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Real-World Landmark Analysis2026
  4. 4Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24‐week multicenter study2024 · 15 citations
  5. 5Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure2024